bluebird bio (NASDAQ:BLUE) Stock Rating Reaffirmed by Cantor Fitzgerald

bluebird bio (NASDAQ:BLUE)‘s stock had its “neutral” rating restated by investment analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports.

Several other research analysts also recently weighed in on the company. Robert W. Baird cut their price target on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Bank of America cut their price target on bluebird bio from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a research note on Thursday, August 15th. Barclays cut their price target on bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 15th. Finally, JPMorgan Chase & Co. downgraded bluebird bio from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 15th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, bluebird bio currently has an average rating of “Hold” and an average target price of $4.74.

bluebird bio Price Performance

Shares of NASDAQ:BLUE opened at $0.50 on Monday. The company has a market capitalization of $54.68 million, a PE ratio of -0.68 and a beta of 0.75. The business has a fifty day moving average price of $0.87 and a two-hundred day moving average price of $1.01. bluebird bio has a 1 year low of $0.48 and a 1 year high of $5.53.

Hedge Funds Weigh In On bluebird bio

Institutional investors have recently modified their holdings of the company. Allegheny Financial Group LTD bought a new position in shares of bluebird bio during the 2nd quarter valued at about $25,000. Dynamic Technology Lab Private Ltd bought a new position in bluebird bio during the 4th quarter worth approximately $37,000. Enterprise Bank & Trust Co bought a new position in bluebird bio during the 1st quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. grew its position in bluebird bio by 189.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 23,933 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in bluebird bio by 48.0% during the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 13,000 shares during the last quarter. 87.43% of the stock is currently owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.